Abiopharma

🔍 Baron Christopher F (Director)

Company: BayCom Corp (BCML)

Report Date: 2026-08-10

Detailed Transactions and Holdings:

• Acquired 8,250 shares of Common Stock at $30.39 per share (Direct)
  Date: 2026-08-10 | Code: P | equity_swap_involved: 0 | shares_owned_after: 9,247.00 | transaction_form_type: 4 | Footnotes: F2
• Holds 52,500 shares of Performance Units (Derivative)
  Date: 2026-08-10 | Code: H | Expires: 2029-07-21 | shares_owned_after: 52,500.00 | Footnotes: F1, F1

Footnotes:

• F1: Represents a grant of 52,500 performance stock units. The performance stock units will be earned and become "Banked PSUs" upon satisfaction of the market vesting condition, which occurs on the date on which the daily volume-weighted average price per share of the issuer's common stock equals or exceeds $40.26 for twenty (20) consecutive trading days, subject to certification by the issuer's compensation committee. The Banked PSUs remain subject to the executive's continued employment through July 1, 2029, and, upon settlement, will be paid 50% in shares of the issuer's common stock and 50% in cash.
• F2: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $30.27 to $30.485, inclusive. The reporting person undertakes to provide BayCom Corp, any security holder of BayCom Corp, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4.